

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Zulresso (brexanolone)

Override(s)	Approval Duration
Prior Authorization	1 time per year

Medications
Zulresso (brexanolone)

APPROVAL CRITERIA

Requests for Zulresso (brexanolone) may be approved if the following criteria are met (Meltzer-Brody 2018):

- I. Individual is 18 years of age or older; **AND**
- II. Individual is 6 months postpartum or less; **AND**
- III. Individual has a diagnosis of moderate to severe postpartum depression consistent with a qualifying score using a standardized screening tool for depression (such as, but not limited to, Hamilton Rating Scale for Depression [HAM-D], Patient Health Questionnaire [PHQ-9], Beck Depression Inventory [BDI], Montgomery-Asberg Depression Rating Scale [MADRS], Edinburgh Postnatal Depression Scale [EPDS]).

Requests for Zulresso (brexanolone) may not be approved for the following:

- I. Individual has end stage renal disease (ESRD) with eGFR < 15 mL/minute/1.73 m².

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0431-19

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

4. The American College of Obstetricians and Gynecologists (ACOG). ACOG Statement on depression screening. 2016 Jan 26. Available from: <https://www.acog.org/About-ACOG/News-Room/Statements/2016/ACOG-Statement-on-Depression-Screening?IsMobileSet=false>. Accessed January 13, 2019.
5. Meltzer-Brody S, Colquhoun H, Riesenber R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet*. 2018;392(10152):1058-1070. Erratum in: *Lancet*. 2018;392(10153):1116.
6. Zulresso [package insert]. Cambridge, MA: Sage Therapeutics, Inc.; 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0431-19